Efficiency of gestagenic preparation “Primolut” in the treatment of patients with endometrial hyperplasia

Abstract

Objective: To study the efficiency of treating dysfunctional uterine bleedings in patients of premenopausal period by Primolut-nor (Germany), each tablet of which contains 5 mg or 10 mg of noretysterone. 74 patients were observed at the age of 40-52 years.

Full Text

Methods: Histological investigation revealed hyperplastic process of various degree (from proliferation to polyposis) in the endometrium of all patients. Duration of treatment and dose was prescribed individually and depended on the extent of hyperplastic process and concomitant extragenital pathology. In polyposis and active forms of glandular hyperplasia the patients were given Primolut-nor in a dose of 10 mg continuously for 3-6 months, and for the following 7-9 months — by a 22-day scheme (from 5th to 26th day of the cycle). Patients with endometrial glandular hyperplasia received the drug by a 22-day scheme: 10 mg for 7-9 months or 5 mg for 12 months. Patients with endometrial proliferation took Primolut-nor in a dose of 5 mg for 6-9 months. There was no increase in arterial pressure and body weight.

Results: No dysfunctional bleedings occurred during treatment. Data of histological, cytological and ultrasound investigations, performed after the therapy, showed a regression of hyperplastic process in all patients.

Conclusion: The results allow to consider gestagenic preparation Primolut-nor to be effective for the treatment of endometrial hyperplasia in women in the premenopausal period.